ライフサイエンスコーパス: subanesthetic

1 hrenia based on NMDA-receptor blockade using subanesthetic administration of ketamine.

2 A subanesthetic, but not anesthetic, dose of ketamine sign

3 3 cells stably transfected with hL1, whereas subanesthetic concentrations of 3-azioctanol (14 microM)

4 Subanesthetic concentrations of 3-diazirinyloctanol enha

5 hat 1-octanol inhibited native T-currents at subanesthetic concentrations with an IC(50) of approxima

6 At subanesthetic concentrations, N(2)O blocks low-voltage-a

7 eurons and Ca(v)3.2 currents in HEK cells at subanesthetic concentrations.

8 in regional brain metabolism induced by the subanesthetic dose may be relevant to effects of ketamin

9 Ketamine, at a subanesthetic dose of 35 mg/kg, substantially increased

10 In the hippocampal formation, the subanesthetic dose of ketamine induced prominent increas

11 A single subanesthetic dose of ketamine normalized glutamate rece

12 ance imaging to investigate the effects of a subanesthetic dose of ketamine on measures of functional

13 transmission that is reversible by an acute, subanesthetic dose of ketamine, along with regionally se

14 e been observed in nonhuman primates after a subanesthetic dose of ketamine, including an impairment

15 se in glutamine/glutamate ratios to a single subanesthetic dose of ketamine, which mirrors the time c

16 ted increased 2-DG uptake in response to the subanesthetic dose of the drug.

17 widely replicated observation that a single subanesthetic dose of the N-methyl-D-aspartate glutamate

18 e observed in select brain regions after the subanesthetic dose, an anesthetic dose of ketamine (100

19 NMDA antagonist ketamine, when injected at a subanesthetic dose, produces working memory deficit and

20 atomically identical to that produced by the subanesthetic dose.

21 n, evidence of an antidepressant response to subanesthetic-dose ketamine has led to a collection of s

22 in healthy volunteers (N = 10) who received subanesthetic doses of ketamine and in a group of clinic

23 Subanesthetic doses of ketamine can be used as a rapid-a

24 nkeys before and after the administration of subanesthetic doses of ketamine during the performance o

25 Subanesthetic doses of ketamine have been shown to exace

26 esent investigation show that anesthetic and subanesthetic doses of ketamine have pronounced effects

27 nkeys before and after the administration of subanesthetic doses of ketamine in a rule-based working

28 s previously demonstrated, administration of subanesthetic doses of ketamine increased 2-DG uptake in

29 Subanesthetic doses of ketamine increased mPFC amino aci

30 f dopamine D(1A) receptors in the effects of subanesthetic doses of ketamine on both behavioral respo

31 Subanesthetic doses of ketamine were repeatedly shown to

32 Subanesthetic doses of ketamine, a noncompetitive NMDA r

33 he antidepressant and anti-stress effects of subanesthetic doses of ketamine, an NMDA receptor antago

34 ate release, following the administration of subanesthetic doses of ketamine, are related to the drug

35 In this paper, we found that subanesthetic doses of ketamine, similar to those used i

36 n sought to define brain regions affected by subanesthetic doses of ketamine, using high resolution a

37 ntional antidepressants drugs, as well as by subanesthetic doses of ketamine.

38 uced simultaneously by the administration of subanesthetic doses of ketamine.

39 Subanesthetic doses of MK-801 and ketamine induced ident

40 Subanesthetic doses of N-methyl-d-aspartate (NMDA) recep

41 Subanesthetic doses of NMDA receptor antagonists induce

42 ional and neutral slides while under various subanesthetic doses of sevoflurane or placebo (no anesth

43 For example, subanesthetic doses of the N-methyl-D-aspartate receptor

44 Accordingly, the effects of subanesthetic doses of the non-competitive NMDA antagoni

45 At subanesthetic doses, ketamine, an N-methyl-D-aspartate g

46 are few MEG/EEG studies examining the acute subanesthetic effects of ketamine infusion in man.

47 uthors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically signifi

48 lved an anaesthesiologist infusing a single, subanesthetic, intravenous dose, and required hospitaliz

49 for such disparate findings by administering subanesthetic ketamine (1-30 mg/kg, i.v.) or vehicle to

50 Subanesthetic ketamine demonstrated promising effects on

51 n = 25 human males) examining the effects of subanesthetic ketamine infusion.

52 This investigation examined the effects of subanesthetic ketamine infusions on motivation for quitt

53 Acute treatment with subanesthetic ketamine, a non-competitive N-methyl-D-asp